EP3801596A4 - BIOMARKERS AND METHODS OF ASSESSING AND METHODS OF TREATING EPILEPTIC SEIZURES VERSUS NON-EPILEPTIC SEIZURES/NON-EPILEPTIC SEIZURES/PSYCHOGENIC NON-EPILEPTIC SEIZURES - Google Patents

BIOMARKERS AND METHODS OF ASSESSING AND METHODS OF TREATING EPILEPTIC SEIZURES VERSUS NON-EPILEPTIC SEIZURES/NON-EPILEPTIC SEIZURES/PSYCHOGENIC NON-EPILEPTIC SEIZURES Download PDF

Info

Publication number
EP3801596A4
EP3801596A4 EP19810368.1A EP19810368A EP3801596A4 EP 3801596 A4 EP3801596 A4 EP 3801596A4 EP 19810368 A EP19810368 A EP 19810368A EP 3801596 A4 EP3801596 A4 EP 3801596A4
Authority
EP
European Patent Office
Prior art keywords
epileptic
seizures
biomarkers
evaluation
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19810368.1A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3801596A1 (en
Inventor
Todd WALLACH
John GLEDHILL
Richard ST.CLAIR
Elizabeth Brand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cognizance Biomarkers Inc
Original Assignee
Evogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evogen Inc filed Critical Evogen Inc
Publication of EP3801596A1 publication Critical patent/EP3801596A1/en
Publication of EP3801596A4 publication Critical patent/EP3801596A4/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G16H20/13—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2857—Seizure disorders; Epilepsy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Medical Informatics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Primary Health Care (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
EP19810368.1A 2018-05-29 2019-05-29 BIOMARKERS AND METHODS OF ASSESSING AND METHODS OF TREATING EPILEPTIC SEIZURES VERSUS NON-EPILEPTIC SEIZURES/NON-EPILEPTIC SEIZURES/PSYCHOGENIC NON-EPILEPTIC SEIZURES Pending EP3801596A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862677452P 2018-05-29 2018-05-29
US201862679298P 2018-06-01 2018-06-01
US201862767762P 2018-11-15 2018-11-15
US201962826088P 2019-03-29 2019-03-29
PCT/US2019/034381 WO2019232037A1 (en) 2018-05-29 2019-05-29 Biomarkers and methods for evaluation and treatment of epileptic vs non-epileptic seizures / no seizures / psychogenic non-epileptic seizures

Publications (2)

Publication Number Publication Date
EP3801596A1 EP3801596A1 (en) 2021-04-14
EP3801596A4 true EP3801596A4 (en) 2023-01-04

Family

ID=68697123

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19810368.1A Pending EP3801596A4 (en) 2018-05-29 2019-05-29 BIOMARKERS AND METHODS OF ASSESSING AND METHODS OF TREATING EPILEPTIC SEIZURES VERSUS NON-EPILEPTIC SEIZURES/NON-EPILEPTIC SEIZURES/PSYCHOGENIC NON-EPILEPTIC SEIZURES

Country Status (6)

Country Link
US (1) US20210199672A1 (ja)
EP (1) EP3801596A4 (ja)
JP (2) JP2021525865A (ja)
AU (1) AU2019279856B2 (ja)
CA (1) CA3101369A1 (ja)
WO (1) WO2019232037A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240197704A1 (en) * 2021-04-09 2024-06-20 Johns Hopkins University Treatment methods and compositions comprising perampanel
EP4426427A2 (en) * 2021-11-02 2024-09-11 Sunbird Bio, Inc. Detection, staging, monitoring and treating a disease or a condition
CN117860892B (zh) * 2023-12-26 2024-08-06 武汉大学中南医院 Il-16阳性神经元在调节恐惧消退记忆中的作用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346270B1 (en) * 1997-07-24 2002-02-12 Alza Corporation Phenytoin therapy
WO2017120166A1 (en) * 2016-01-04 2017-07-13 Evogen, Inc. Biomarkers and methods for detection of seizures and epilepsy
WO2018213437A1 (en) * 2017-05-16 2018-11-22 Evogen, Inc. Biomarkers and methods for detection of seizures and epilepsy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2208230C2 (ru) * 1997-10-02 2003-07-10 Айкос Корпорейшн Icam-4 и его диагностическое использование
IL124444A0 (en) * 1998-05-12 1998-12-06 Svetlana Dolina Biochemical approach to diagnosis of predisposition to epilepsy and monitoring of antiepileptic treatment
WO2006133508A1 (en) * 2005-06-16 2006-12-21 Bionomics Limited Methods of treatment, and diagnosis of epilepsy by detecting mutations in the scn1a gene
US20080249058A1 (en) * 2007-04-05 2008-10-09 Erik Roberson Agents that reduce neuronal overexcitation
WO2012116264A1 (en) * 2011-02-24 2012-08-30 The Trustees Of The University Of Pennsylvania Biomarkers for seizures
DK178081B9 (en) * 2013-06-21 2015-05-11 Ictalcare As Method of indicating the probability of psychogenic non-epileptic seizures
US20170326330A1 (en) * 2016-05-13 2017-11-16 Grzegorz Bulaj Multimodal platform for treating epilepsy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346270B1 (en) * 1997-07-24 2002-02-12 Alza Corporation Phenytoin therapy
WO2017120166A1 (en) * 2016-01-04 2017-07-13 Evogen, Inc. Biomarkers and methods for detection of seizures and epilepsy
WO2018213437A1 (en) * 2017-05-16 2018-11-22 Evogen, Inc. Biomarkers and methods for detection of seizures and epilepsy

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BRIGO FRANCESCO ET AL: "Postictal serum creatine kinase for the differential diagnosis of epileptic seizures and psychogenic non-epileptic seizures: a systematic review", JOURNAL OF NEUROLOGY - ZEITSCHRIFT FUER NEUROLOGIE, SPRINGER VERLAG, BERLIN, DE, vol. 262, no. 2, 14 May 2014 (2014-05-14), pages 251 - 257, XP035450895, ISSN: 0340-5354, [retrieved on 20140514], DOI: 10.1007/S00415-014-7369-9 *
CHIUNG-CHIH CHANG ET AL: "Clinical significance of serological biomarkers and neuropsychological performances in patients with temporal lobe epilepsy", BMC NEUROLOGY, BIOMED CENTRAL LTD., LONDON, GB, vol. 12, no. 1, 14 March 2012 (2012-03-14), pages 15, XP021124896, ISSN: 1471-2377, DOI: 10.1186/1471-2377-12-15 *
EHSAN TAJAMMUL ET AL: "Sensitivity and specificity of paired capillary prolactin measurement in diagnosis of seizures", JOURNAL OF EPILEPSY, vol. 9, no. 2, 1 June 1996 (1996-06-01), GB, pages 101 - 105, XP055908594, ISSN: 0896-6974, Retrieved from the Internet <URL:https://www.sciencedirect.com/science/article/pii/0896697496000060/pdf?md5=15f098a33aaaaf1eea0b162dca14a981&pid=1-s2.0-0896697496000060-main.pdf> DOI: 10.1016/0896-6974(96)00006-0 *
POLLARD JOHN R ET AL: "Predictive-Blood-Test-for-Seizures--post-hoc-Assessment-of-Plasma-Biomarkers", 2016 AES ANNUAL MEETING, 22 November 2016 (2016-11-22), pages 1 - 3, XP055908433, Retrieved from the Internet <URL:https://cms.aesnet.org/abstractslisting/predictive-blood-test-for-seizures--post-hoc-assessment-of-plasma-biomarkers> [retrieved on 20220404] *
See also references of WO2019232037A1 *

Also Published As

Publication number Publication date
JP2024001063A (ja) 2024-01-09
JP2021525865A (ja) 2021-09-27
WO2019232037A1 (en) 2019-12-05
AU2019279856A1 (en) 2021-01-21
EP3801596A1 (en) 2021-04-14
CA3101369A1 (en) 2019-12-05
US20210199672A1 (en) 2021-07-01
AU2019279856B2 (en) 2024-03-07

Similar Documents

Publication Publication Date Title
EP3734289A4 (en) FULLY AUTOMATIC MULTI-CHANNEL DETECTION APPARATUS FOR CIGARETTE BUTT DROP TRENDS, AND DETECTION METHOD
EP3278113A4 (en) Method for predicting risk of cognitive deterioration
EP3716837A4 (en) SYSTEM AND METHOD FOR DETECTION OF NEUROLOGICAL DISORDERS AND MEASUREMENT OF GENERAL COGNITIVE PERFORMANCE
EP3247267A4 (en) Method and apparatus for improving cognitive performance
EP3399997A4 (en) BIOMARKERS AND METHODS FOR DETECTING EPILEPTIC CRISES AND EPILEPSY
EP3896453A4 (en) SYSTEM FOR EVALUATING THE OVARIAN RESERVE FUNCTION OF A SUBJECT AND METHOD
EP3435860C0 (en) METHODS FOR DETERMINING COGNITIVE IMPAIRMENT WITH MAGNETOENCEPHALOGRAPHY DATA
EP3347493A4 (en) BIOMARKERS AND METHOD FOR THE DIAGNOSIS AND PROGNOSIS OF EASY TRAUMATIC BRAIN INJURIES
EP3642977A4 (en) METHOD AND DEVICE FOR SYNCHRONIZING SIGNALS AND PBCH BLOCK IMPROVEMENT
EP3646328A4 (en) APPARATUS AND METHOD FOR ABSOLUTE QUANTIFICATION OF BIOMARKERS ALLOWING A DIAGNOSIS OF SOLID TUMOR
EP3761849A4 (en) METHOD FOR DETECTING AND/OR PREDICTING EPILEPTIC EVENTS
EP3298954A4 (en) METHOD AND DEVICE FOR DETERMINING THE TEMPERING STATUS OF A BRAIN
EP3359022A4 (en) METHOD AND SYSTEM FOR PRE-PROCESSING AN EEG SIGNAL FOR COGNITIVE LOAD MEASUREMENT
EP3801596A4 (en) BIOMARKERS AND METHODS OF ASSESSING AND METHODS OF TREATING EPILEPTIC SEIZURES VERSUS NON-EPILEPTIC SEIZURES/NON-EPILEPTIC SEIZURES/PSYCHOGENIC NON-EPILEPTIC SEIZURES
EP3390367A4 (en) METHOD FOR THE PREVENTION AND / OR TREATMENT OF AGE-RELATED COGNITIVE IMPAIRMENT AND NERVE IGNITION
EP3703568A4 (en) APPARATUS AND METHOD FOR EVALUATING COGNITIVE FUNCTION
EP3740201A4 (en) METHOD FOR TREATMENT OF ACID-BASE DISORDER
IL291687A (en) Methods for treating myelofibrosis and related conditions
EP3335041A4 (en) BIOMARKER FOR THE TREATMENT OF ALOPECIA AREATA
EP3703707A4 (en) METHOD FOR TREATMENT OF ACID-BASE DISORDER
EP3010404A4 (en) Method of indicating the probability of psychogenic non-epileptic seizures
HK1248810A1 (zh) 用於角膜擴張性疾病的診斷和預後的生物標記物
EP3624826A4 (en) BIOMARKERS AND METHODS OF SEIZURE DETECTION AND EPILEPSY
EP3267731A4 (en) Method and apparatus for determining central frequency channel number of carrier
EP3274709A4 (en) Biomarkers and methods of diagnosing and prognosing mild traumatic brain injuries

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201222

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101ALI20220602BHEP

Ipc: G16H 50/30 20180101ALI20220602BHEP

Ipc: G16H 50/20 20180101ALI20220602BHEP

Ipc: G01N 33/53 20060101ALI20220602BHEP

Ipc: A61K 38/17 20060101AFI20220602BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20221202

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101ALI20221128BHEP

Ipc: G16H 50/30 20180101ALI20221128BHEP

Ipc: G16H 50/20 20180101ALI20221128BHEP

Ipc: G01N 33/53 20060101ALI20221128BHEP

Ipc: A61K 38/17 20060101AFI20221128BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: COGNIZANCE BIOMARKERS LLC

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240328

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: COGNIZANCE BIOMARKERS, INC.